MegazoneCloud, AI Transformation Collaboration with Aizen Science in New Drug Development

• High-performance cloud infrastructure and operational support...Full-scale joint sales and technical cooperation targeting new drug development companies

Megazone Cloud (CEO Yong Yim), a leading AI and cloud company, is promoting digital transformation in the new drug development field with AIGEN Science (CEO Jae-woo Kang), an AI new drug development company.

The two companies signed a 'Memorandum of Understanding (MOU) for AI-based new drug development cooperation' on the 16th at Megazone Cloud's liaison office in Yeoksam-dong, Seoul, with key executives from both sides in attendance.

AIGEN Science is an AI-based new drug development specialist company founded through Korea University's technology holding company, and is efficiently developing small molecule synthetic new drugs in the field of intractable diseases through its own AI platform. Last year, it was selected for the Scale-up TIPS program, which is jointly supported by the Ministry of SMEs and Startups and private investors to promote technological innovation and global market entry of promising companies with high growth potential.

Through this agreement, the two companies plan to conduct joint sales targeting pharmaceutical customers such as new drug development companies and clinical trial contract research organizations (CROs), and expand cloud-based AI utilization.

Megazone Cloud will provide high-performance GPU-based cloud infrastructure and operational support and technical consulting to ensure smooth operation of AIGEN Science's AI-based new drug development platform AIGEN InSight and AIGEN ChemTailor, and the biomedical-specialized language model Meerkat. AIGEN Science will participate in joint business development in the pharmaceutical field based on its own AI technology.

Additionally, the two companies plan to conduct various joint marketing activities including seminars, conferences, and promotions, and will gradually expand their cooperation scope by sharing cloud operational experience and infrastructure optimization expertise.

AIGEN Science CEO Jae-woo Kang said, "To enhance the results of AI-based new drug development, technology and infrastructure must be designed together," and added, "Through cooperation with Megazone Cloud, we will secure both industrial applicability and efficiency."

Megazone Cloud CEO Yong Yim said, "Among cases where AI technology is actually transforming industries, new drug development is one of the fields with the greatest potential and ripple effects," and added, "Megazone Cloud will continue to expand AI technology support so that domestic new drug development companies, including AIGEN Science, can grow by implementing optimal technology in a stable environment."

Megazone Cloud is an AI and cloud-native leading company with 2,000 cloud and AI technology experts, and is a digital transformation (DX) partner for approximately 7,000 customers at home and abroad. Based on strategic partnerships with major global and domestic cloud service providers (CSPs), it supports customer innovation and growth through 140+ ISV partners and self-developed cloud, AI, and security solutions. Under the vision of 'Transform, Tomorrow, Together,' the company is creating customers' future competitiveness together through technology, data, and the passion of its employees. Megazone Cloud operates local subsidiaries in 9 countries including Korea, North America, Japan, Southeast Asia, and Oceania, and is growing together with customers as a global partner.